Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evogene (EVGN) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Evogene (EVGN) over the last 15 years, with Q3 2025 value amounting to $8.8 million.

  • Evogene's Total Liabilities rose 17218.5% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year increase of 17218.5%. This contributed to the annual value of $25.0 million for FY2024, which is 1164.35% up from last year.
  • Evogene's Total Liabilities amounted to $8.8 million in Q3 2025, which was up 17218.5% from $21.6 million recorded in Q2 2025.
  • In the past 5 years, Evogene's Total Liabilities ranged from a high of $28.2 million in Q4 2022 and a low of -$82.1 million during Q1 2021
  • For the 5-year period, Evogene's Total Liabilities averaged around -$6.9 million, with its median value being $10.9 million (2021).
  • In the last 5 years, Evogene's Total Liabilities crashed by 6291.46% in 2021 and then skyrocketed by 18631.37% in 2025.
  • Quarter analysis of 5 years shows Evogene's Total Liabilities stood at $22.7 million in 2021, then rose by 24.48% to $28.2 million in 2022, then dropped by 20.5% to $22.4 million in 2023, then grew by 11.64% to $25.0 million in 2024, then plummeted by 64.7% to $8.8 million in 2025.
  • Its last three reported values are $8.8 million in Q3 2025, $21.6 million for Q2 2025, and $21.9 million during Q1 2025.